Healthcare · Medical - Instruments & Supplies
Price
$3.80
Market Cap
$11.5M
Employees
69
Beta
-2.22
Avg Volume
61,311
CEO
Kathy Lee-Sepsick
Business Description
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
Business History
Price Overview
Last updated: Jun 27, 2026 9:00am (just now)$3.80
+0.20 (+5.56%)
Day Range
$3.56 – $3.93
52-Week Range
$3.50 – $22.20
50-Day MA
$6.78
200-Day MA
$10.89
Volume
51,552.00
Share Structure
Outstanding
3,019,534.00
Float
2,495,041.00
Free Float
82.6%
High free float
— 82.6% of shares trade freely, ~17.4% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Small absolute float (2.5M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.40
Stock Price: $3.80
EPS (Diluted): -9.40
EPS (Diluted): -9.40
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
3.88
Stock Price: $3.80
Total Equity: $5.87M
Shares: 1,977,460
Total Equity: $5.87M
Shares: 1,977,460
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-1.15
Market Cap: $11.47M
Total Debt: $3.18M
Cash: $9.27M
EBITDA: -$15.89M
Total Debt: $3.18M
Cash: $9.27M
EBITDA: -$15.89M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$18.2M
Market Cap: $11.47M
Total Debt: $3.18M
Cash: $9.27M
Total Debt: $3.18M
Cash: $9.27M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
9.93
Stock Price: $3.80
Revenue: $2.29M
Shares: 1,977,460
Revenue: $2.29M
Shares: 1,977,460
EV/Sales (Total value vs revenue — works when P/E can't)
API7.94
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
62.0%
Gross Profit: $1.42M
Revenue: $2.29M
Revenue: $2.29M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-767.0%
Operating Income: -$17.59M
Revenue: $2.29M
Revenue: $2.29M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-812.3%
Net Income: -$18.63M
Revenue: $2.29M
Revenue: $2.29M
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-258.1%
Net Income: -$18.63M
Total Equity: $5.87M
Total Equity: $5.87M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-118.3%
Operating Income: -$17.59M
Tax Rate: 0.0%
Equity: $5.87M
Total Debt: $3.18M
Cash: $9.27M
Tax Rate: 0.0%
Equity: $5.87M
Total Debt: $3.18M
Cash: $9.27M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
4.53
Current Assets: $16.46M
Current Liabilities: $3.64M
Current Liabilities: $3.64M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.54
Short-Term Debt: $0.00
Long-Term Debt: $3.18M
Total Debt: $3.18M
Total Equity: $5.87M
Long-Term Debt: $3.18M
Total Debt: $3.18M
Total Equity: $5.87M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$1.16
Revenue: $2.29M
Shares: 1,977,460
Shares: 1,977,460
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$2.97
Total Equity: $5.87M
Shares: 1,977,460
Shares: 1,977,460
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-9.72
Operating CF: -$18.69M
CapEx: -$525,007
Shares: 1,977,460
CapEx: -$525,007
Shares: 1,977,460
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $3.80
Stock Price: $3.80
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$18.63M
Net Income: -$18.63M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares FEMY against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 22, 2026 8:03pm (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $1.2M | $1.2M | $1.1M | $1.6M | $2.3M |
| Cost of Revenue | $370,384 | $441,938 | $380,069 | $544,903 | $872,400 |
| Gross Profit | $809,305 | $764,280 | $691,901 | $1.1M | $1.4M |
| Operating Expenses | $9.1M | $12.4M | $15.2M | $18.9M | $19.0M |
| Operating Income | -$8.3M | -$11.6M | -$14.5M | -$17.8M | -$17.6M |
| Net Income | -$7.5M | -$11.4M | -$14.2M | -$18.8M | -$18.6M |
| EBITDA | -$6.6M | -$10.5M | -$13.2M | -$16.3M | -$15.9M |
| EPS | $-12.80 | $-19.40 | $-18.60 | $-16.80 | $-9.40 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 22, 2026 8:03pm (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $24.8M | $13.0M | $21.7M | $3.5M | $9.3M |
| Total Current Assets | $25.6M | $14.1M | $23.2M | $8.0M | $16.5M |
| Total Assets | $28.6M | $16.9M | $27.8M | $12.4M | $20.7M |
| Current Liabilities | $1.7M | $1.5M | $3.1M | $8.6M | $3.6M |
| Long-Term Debt | $0 | $0 | $4.3M | $0 | $3.2M |
| Total Liabilities | $2.2M | $1.7M | $9.4M | $10.1M | $14.9M |
| Total Equity | $26.3M | $15.2M | $18.4M | $2.3M | $5.9M |
| Retained Earnings | -$82.7M | -$94.1M | -$108.4M | -$127.2M | -$145.8M |
Cash Flow (Annual)
Last updated: Jun 22, 2026 8:03pm (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$7.9M | -$10.7M | -$11.3M | -$19.4M | -$18.7M |
| Capital Expenditure | $-306,868 | $-407,475 | $-143,917 | $-761,706 | $-525,007 |
| Free Cash Flow | -$8.2M | -$11.1M | -$11.4M | -$20.2M | -$19.2M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $21.5M | -$11.8M | $8.8M | -$18.3M | $5.8M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 9:00am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$10.0M $7.9M – $13.8M
|
$21.7M $19.2M – $25.9M
|
$51.8M $45.7M – $61.8M
|
$94.5M $83.4M – $112.7M
|
| EBITDA |
-$10.0M -$13.8M – -$7.9M
|
-$21.7M -$25.9M – -$19.2M
|
-$51.8M -$61.8M – -$45.7M
|
-$94.5M -$112.7M – -$83.4M
|
| Net Income |
-$10.4M -$11.1M – -$9.7M
|
-$8.3M -$10.9M – -$5.7M
|
$1.3M $1.1M – $1.6M
|
$18.6M $15.8M – $23.3M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 22, 2026 8:03pm (4d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +2.2% | -11.1% | +52.0% | +40.8% |
| Gross Profit Growth | -5.6% | -9.5% | +56.7% | +31.1% |
| Operating Income Growth | -39.1% | -25.1% | -22.6% | +1.1% |
| Net Income Growth | -51.2% | -25.0% | -32.1% | +1.0% |
| EBITDA Growth | -60.1% | -25.6% | -24.0% | +2.7% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-03-30 | Canning John Charles | A-Award | 150,000.00 | $0.38 | $57,000 |
| 2026-03-30 | Canning John Charles | 0.00 | $0.00 | $0 | |
| 2026-03-19 | Lee-Sepsick Kathy | A-Award | 68,244.00 | $0.58 | $39,582 |
| 2026-03-19 | Elefant Dov | A-Award | 34,122.00 | $0.58 | $19,791 |
| 2026-03-19 | Eichenbaum Kenneth D. | A-Award | 102,366.00 | $0.58 | $59,372 |
| 2026-03-19 | Larsen Charles | A-Award | 34,122.00 | $0.58 | $19,791 |
| 2026-03-18 | Eichenbaum Kenneth D. | 0.00 | $0.00 | $0 | |
| 2025-11-07 | Eichenbaum Kenneth D. | 102,366.00 | $0.81 | $82,916 | |
| 2025-11-07 | Eichenbaum Kenneth D. | 102,366.00 | $0.73 | $74,727 | |
| 2025-11-07 | Eichenbaum Kenneth D. | 102,366.00 | $0.92 | $94,177 | |
| 2025-11-07 | Eichenbaum Kenneth D. | 102,366.00 | $1.10 | $112,603 | |
| 2026-03-18 | Eichenbaum Kenneth D. | A-Award | 35,200.00 | $0.60 | $21,120 |
| 2026-03-17 | PharmaCyte Biotech, Inc. | 0.00 | $0.00 | $0 | |
| 2026-03-17 | Silverman Joshua | 0.00 | $0.00 | $0 | |
| 2026-02-19 | Lee-Sepsick Kathy | A-Award | 447,000.00 | $0.00 | $0 |
| 2026-02-19 | Lee-Sepsick Kathy | A-Award | 282,000.00 | $0.00 | $0 |
| 2026-02-19 | Elefant Dov | A-Award | 173,000.00 | $0.00 | $0 |
| 2026-02-19 | Elefant Dov | A-Award | 169,000.00 | $0.00 | $0 |
| 2026-02-02 | Sipos Jeremy Alexander | A-Award | 80,000.00 | $0.00 | $0 |
| 2025-12-16 | Sipos Jeremy Alexander | 0.00 | $0.00 | $0 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for FEMY — it's generated by the pipeline (
market-narrative step).
No community reviews yet for FEMY.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30